Blood test may forecast lymphoma prognosis
NCT ID NCT07480837
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether tracking tiny bits of tumor DNA in the blood (ctDNA) can help predict how B-cell non-Hodgkin lymphoma will progress. Researchers will collect blood samples from 60 patients before and during treatment. The goal is to see if changes in ctDNA levels match with how well patients respond to therapy, but this is an observational study only — no new treatment is being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- New drug combo aims to tackle Hard-to-Treat lymphoma
- New daily pill aims to tackle Hard-to-Treat lymphoma
- New drug candidate SHR-3079 targets Hard-to-Treat lymphoma